Sopharma AD (WSE:SPH)

Market Cap	3.81B +81.9%
Revenue (ttm)	5.68B +22.6%
Net Income	288.18M +75.0%
EPS	0.84 +154.0%
Shares Out	n/a
PE Ratio	13.23
Forward PE	n/a
Dividend	0.36 (5.18%)
Ex-Dividend Date	Dec 18, 2025

Volume	827
Average Volume	630
Open	7.50
Previous Close	7.02
Day's Range	7.42 - 7.50
52-Week Range	4.00 - 16.00
Beta	0.04
RSI	44.44
Earnings Date	Mar 2, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1933
• Employees: 5,905
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SPH

Financial Performance

In 2025, Sopharma AD's revenue was 2.63 billion, an increase of 22.57% compared to the previous year's 2.15 billion. Earnings were 133.52 million, an increase of 74.97%.

Financial numbers in BGN